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Background: DrrAB is dedicated to export of
doxorubicin in Streptomyces peucetius, an
organism which produces this anticancer drug.
Whether this prototype system can export other
drugs has not been investigated.
Results: DrrAB exports multiple drugs efficiently.
Conclusion: Substrate specificity of DrrAB
overlaps with known bacterial and human multidrug resistance proteins.
Significance: This study suggests common
mechanisms and origin for DrrAB and other MDR
proteins.

rifampicin) of the well-studied multi-drug
transporters inhibit DrrAB-mediated Dox
transport with high efficiency, indicating that
they are also substrates of the DrrAB pump.
Kinetic studies show that inhibition of
doxorubicin transport by Hoechst 33342 and
rifampicin occurs by a competitive mechanism
whereas verapamil inhibits transport by a noncompetitive mechanism, thus suggesting the
possibility of more than one drug binding site in
the DrrAB system. This is the first in-depth
study of a drug resistance system from a
producer organism, and it shows that a
dedicated efflux system like DrrAB contains
specificity for multiple drugs. The significance
of these findings in evolution of poly-specificity
in drug resistance systems is discussed.
Multidrug resistance (MDR) has emerged
as a major clinical problem in recent years both for
the treatment of infectious diseases and for
chemotherapy of cancer. Although many different
mechanisms for drug resistance are known, a
common strategy consists of active efflux of drugs
from the cells (1).
Drug transporters are
categorized into either single-drug efflux systems
(which are specific for a drug or a group of drugs)
or multi-drug efflux systems that exhibit a broad
specificity and can transport structurally and
functionally unrelated compounds. These proteins
function as either primary active (belonging to the
ATP Binding Cassette superfamily) or secondary
active transporters (2). The phenomenon of
multidrug resistance was first characterized in
mammalian cancer cells, where exposure to

ABSTRACT
The soil bacterium Streptomyces
peucetius produces two widely used anticancer
antibiotics doxorubicin and daunorubicin.
Present within the biosynthesis gene cluster in
S. peucetius is the drrAB operon which codes
for a dedicated ABC-type transporter for the
export of these two closely related antibiotics.
Because of its dedicated nature, the DrrAB
system is believed to belong to the category of
single-drug transporters. However, whether it
also contains specificity for other known
substrates of multidrug transporters has never
been tested. In this study, we demonstrate
under both in vivo and in vitro conditions that
the DrrAB system can transport not only
doxorubicin but is also able to export two most
commonly studied MDR substrates, Hoechst
33342 and ethidium bromide. Moreover, we
demonstrate that many other substrates
(including
verapamil,
vinblastine,
and
1
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accommodate
several
ligand
molecules
simultaneously (8). However, the drug binding
cavity, though present in the membrane, was
found to be accessible to the periplasmic domain.
Thus, in contrast to Pgp (where the drug portals
are located in the membrane), the periplasmic
region of AcrB seems to play a major role in
determining substrate specificity, suggesting
differences between the mechanisms of different
MDR proteins.
The bacterial ABC drug transporters that
have also been studied in significant detail include
the E. coli ABC transporter MsbA (responsible for
export of Lipid A, the core moiety of LPS), L.
lactis homologue LmrA and S. aureus Sav1866
(3,9,10). All of these proteins have been shown to
transport multiple drugs. Interestingly, MsbA was
found to contain overlapping substrate specificity
with LmrA and Sav1866 (11). Some newly
identified members, such as VcaM from Non-O1
Vibrio cholerae and the YccC (BmrA) from
Bacillus subtilis were also shown to transport
multiple drugs (12,13). Therefore, a significant
progress has indeed been made in understanding
the phenomenon of multidrug resistance.
However, the available information is based on the
analysis of only a handful of drug transporters
described above. Most other annotated drug
transporters, especially those found in the
antibiotic/drug producer organisms, have not been
analyzed for their ability to confer MDR.
Moreover, not much is known about why and how
the ability to confer multidrug resistance evolves.
In this study, we analyzed the ABC
transporter DrrAB, which confers self-resistance
to two related anticancer antibiotics doxorubicin
(Dox) and daunorubicin (Dnr) in the producer soil
organism Streptomyces peucetius. The genes for
this system are present in an operon located within
the gene cluster for biosynthesis of Dox and Dnr,
therefore they code for a dedicated transporter for
these antibiotics. The DrrAB system represents
the simplest form of an ABC drug transporter,
which is assembled from two molecules each of
DrrA (the catalytic subunit) and DrrB (integral
membrane subunit) (14). In the mammalian Pgp,
the two catalytic and two integral membrane
domains are naturally fused into a single large
polypeptide, possibly the result of an evolutionary
gene fusion event (15). Both DrrAB and Pgp
2
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anticancer drugs was seen to result in overexpression of ABC-type efflux pumps, such as Pglycoprotein and MRP1 (2). These proteins have
since been shown to transport hundreds of
structurally unrelated compounds, including
amphipathic anti-cancer drugs, peptides, and
fluorescent dyes, etc., thus conferring MDR in
cancer cells. MDR is also widespread among
bacteria - the best known ABC family members
include the bacterial proteins LmrA and LmrCD in
L. lactis, Sav1866 in S. aureus, and MsbA in E.
coli.
While most of the ABC proteins
mentioned above have served as useful models to
characterize and understand the basis of MDR
(2,3), the most extensive biochemical analysis of
the nature of multidrug specificity has been carried
out with Pgp (4,5). Together the analyses carried
out by many different groups suggested that Pgp
contains a large drug binding chamber which can
accommodate several drugs simultaneously. It was
also suggested that the drug binding chamber in
Pgp is lined by several trans-membrane (TM)
helices, including TMs 4-6 in TMD1 and TMs 912 in TMD2 (4). Most recently, the crystal
structure of Pgp confirmed many findings of the
biochemical analysis and showed that Pgp indeed
contains a large and flexible drug binding cavity
made of mostly hydrophobic and aromatic
residues (6). Different drugs were seen to interact
with residues in different parts of the flexible
cavity, mostly through hydrophobic interactions,
thus providing an explanation for the poly-specific
nature of Pgp. The crystal structure of Pgp also
revealed that some drugs were bound to a single
site, while some others bound to two different
locations within the cavity. The drug binding
cavity of Pgp was found to reside within the cell
membrane, and it showed the presence of two
portals formed by TMs 4 and 6 and TMs 10 and
12 which allow direct entry of hydrophobic
molecules from the membrane (6).
This
observation supports previous models, which
proposed that Pgp can extract drugs directly from
the lipid bilayer and remove them by a
hydrophobic vacuum cleaner mechanism (7). The
crystal structure of another MDR protein, AcrB, a
secondary-active transporter, is also available.
This structure also showed the presence of a very
large central drug binding cavity, which could

findings of this paper demonstrate for the first time
that the dedicated Dox transport system, DrrAB,
can recognize and transport multiple drugs. This
study highlights overlaps between the substrate
specificity of the DrrAB system and Pgp and
points to a common mechanism, and perhaps
origin, for most MDR proteins.
EXPERIMENTAL PROCEDURES
Materials used – verapamil, vinblastine,
rifampicin, doxorubicin hydrochloride, ethidium
bromide, quinine, quinidine, colchicine, succinate,
sodium fluoride, NADH (β-Nicotinamide adenine
dinucleotide reduced disodium salt hydrate), ATP,
GTP, and sodium o-vanadate were purchased from
Sigma Aldrich. Hoechst 33342, rhodamine 123,
rhodamine 6G, rhodamine B, and TMRM
(Tetramethyl rhodamine) were obtained from Life
Technology.
Creatine kinase and creatine
phosphate were purchased from Roche
Diagnostics.
In vivo Dox efflux in cells – E. coli
LE392ΔuncIC cells (Table 1) containing either
vector pSU2718 or pDX101(pSU2718/drrAB)
were grown in 200 ml TEA medium [50 mM
triethanolamine HCl, pH 6.9, 15 mM KCl, 10mM
(NH4)2SO4, 1mM MgSO4] supplemented with
0.5% (w/v) glycerol, 2.5 µg/ml thiamine, 0.5%
(w/v) peptone and 0.15% (w/v) succinate to midlog phase and induced with 0.1 mM IPTG for 1 hr.
The harvested cells were washed twice and
resuspended in 100 µl TEA buffer. 10 μl of the
cell suspension from above was incubated in 3 ml
of TEA medium containing 10 μM doxorubicin
and 5 mM 2,4-dinitrophenol for 11 h at 37 °C.
The loaded cells were washed twice with 0.1 mM
MOPS buffer, pH 7.0 and resuspended in 3 ml of
MOPS buffer containing 2 mM MgSO4. The
fluorescence spectra were recorded on an
Alphascan-2
spectrofluorometer
(Photon
Technology International, London, Ontario,
Canada).
The excitation wavelength for
doxorubicin was 480 nm, and emission was
monitored at 590 nm. The excitation and emission
slit widths were both set at 1.00 mm, and a timebased script was run. After an initial recording of
fluorescence for 100 s at 37 °C, energy was
provided in the form of either 20 mM glucose or
20 mM succinate, and recording was continued for
an additional 400 s. The rate of Dox efflux was
3
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confer resistance to the anticancer agents Dox and
Dnr: DrrAB in the producer organism and Pgp in
cancer cells. Therefore, the overall structure and
function of the DrrAB transporter bears significant
similarity to Pgp even though these two
transporters belong to different classes of ABC
proteins (16). Subcloning of the drrAB locus in
E. coli was previously shown to confer
doxorubicin resistance in this host (17). It was
also previously shown that the DrrAB system
confers resistance to Dox by an energy-dependent
efflux mechanism (18). However, it is not known
if this system is specific for Dox and Dnr, or if,
like Pgp, it can also recognize and transport
multiple drugs. Since this is a prototype drug
resistance mechanism found in the producer
organism, analysis of this system could shed light
on the nature of substrate specificity and elucidate
how the ability to confer multidrug resistance
evolves in proteins.
In this paper, we provide in-depth
characterization of drug transport by the DrrAB
system and show that, contrary to the generally
held assumption, this system forms a multidrug
transporter. Using both E. coli whole cells and
inside-out membrane vesicles (IOVs), it is shown
that the DrrAB system can efficiently transport not
only Dox, but also Hoechst 33342 (H 33342) and
ethidium bromide (EtBr), two substrates most
commonly used to establish the MDR phenotype
(3,10,19).
We also found that the DrrABmediated Dox efflux is inhibited by a number of
other well-characterized MDR substrates, such as
verapamil, rifampicin, vinblastine and colchicine,
suggesting that these drugs are also substrates of
the DrrAB pump. Interestingly, DrrAB-mediated
efflux could be coupled to the energy of either
ATP or GTP hydrolysis, and, as expected, the
function of this transporter was found to be
completely independent of the proton motive force
(pmf). Since multiple drugs were found to inhibit
Dox efflux by the DrrAB system, kinetics analysis
was carried out to understand the mechanism of
inhibition and interaction of drugs with DrrAB.
Our studies revealed that inhibition of Dox efflux
by H 33342 and rifampicin occurs by a
competitive mechanism, whereas verapamil
inhibits Dox transport by a non-competitive
mechanism, suggesting that the DrrAB transporter
may contain at least two drug binding sites. The

100 s and 200 s. To determine the kinetics of Dox
transport, efflux was measured at a wide range of
Dox concentrations (0.1 µM to 6 µM). The data
were fitted by the Michaelis–Menten equation (V
= Vmax[S]/(Km) + [S]) by Sigma Plot Kinetics
software in Single-Substrate Format.
In vitro Hoechst 33342 Efflux in IOVs –
The DrrAB-mediated efflux of H 33342 was
studied in IOVs, as described above for Dox
Efflux with some modifications. Briefly, 250 µg
IOVs were resuspended in 3 ml 1x PBS buffer, pH
7.4 supplemented with 0.1 mg/ml creatine kinase
and 5 mM creatine phosphate and various
concentrations of H 33342 (0.1 µM to 2.5 µM).
The excitation and emission wavelengths of H
33342 were 355 nm and 457 nm, respectively.
The rate of H 33342 transport was determined
from the initial slope of the linear range
between100 s to 200 s.
Vanadate inhibition of Dox efflux in IOVs
– 250 µg IOVs were resuspended in 3 ml 1x PBS
buffer, pH 7.4 supplemented with 0.1 mg/ml
creatine kinase, 5 mM creatine phosphate, 1 µM
Dox, and various concentrations of sodium ovanadate (0 µM – 100 µM). The measurement of
Dox efflux was performed, as described above.
The rate of Dox transport was determined from the
slope of the linear range between 100 s and 200 s.
Determination of IC50 – 250 µg IOVs were
resuspended in 3ml 1xPBS buffer, pH 7.4
supplemented with 0.1 mg/ml creatine kinase and
5 mM creatine phosphate, 1 µM Dox, and various
concentrations of the inhibitory drug.
The
measurement of Dox efflux was performed, as
described above. The rate of Dox transport was
determined from the slope of the initial linear
range between 100 s and 200 s. Designating the
efflux rate of the sample without inhibitor as 1.0,
the relative rate of each sample was calculated.
The average data of three independent experiments
were plotted by ‘Scatter Plot with simple error
bars’ in Sigma Plot 11.0 software and fitted by the
dynamic curve fit (equation: y = ae-bx, x:
concentration of inhibitor; y: relative rate). The
IC50 value was determined based on the
concentration of the drug that brings about 50%
inhibition of the DrrAB-mediated Dox efflux at a
Dox concentration of 1 µM.
Kinetics of Dox efflux inhibition by known
MDR substrates – To study the kinetic inhibition
4
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determined from the slope in the steady-state
range (300 s to 500 s). Where indicated, 10 mM
sodium fluoride was added as inhibitor of ATP
synthesis.
In vivo ethidium bromide efflux in cells –
E. coli LE392ΔuncIC cells containing the
indicated plasmid were grown, induced, and
loaded with various concentrations (1 µM to 100
µM) of EtBr, as described above, except that the
loading time used was 1 hr at 37 °C. The loaded
cells were washed twice with 0.1 mM MOPS, pH
7.0 and resuspened in 3 ml MOPS buffer
containing 2 mM MgSO4. EtBr efflux from
loaded cells was measured fluorometrically (exi,
500 nm; emi, 580 nm) on an Alphascan-2
spectrofluorometer
(Photon
Technology
International). After 100 s, energy was provided
in the form of 20 mM glucose. The recording was
continued for additional 400 s. The rate of EtBr
efflux was determined from the slope in the
steady-state range (300 s to 500 s).
Preparation of inside-out membrane
vesicles (IOVs) – E. coli LE392ΔuncIC cells
containing indicated plasmids were grown in 1 L
LB medium at 37 °C until mid-log phase and
induced with 0.25 mM IPTG at 37 °C for 3 hr.
The cells pellet was re-suspended in 20 ml 1xPBS
buffer, pH 7.4 and lysed with French Press at
16,000 p.s.i. twice. The membrane fraction was
prepared according to the previously published
protocol (14), except that the membrane vesicles
were washed twice with 20 ml 1xPBS buffer.
In vitro Dox efflux in IOVs and kinetic
analysis – 250 µg IOVs were resuspended in 3 ml
1x PBS buffer, pH 7.4 supplemented with 0.1
mg/ml creatine kinase and 5 mM creatine
phosphate.
Dox was added to a final
concentration of 1.0 µM, or as indicated. The
fluorescence spectra were recorded on an
Alphascan-2-spectrofluorometer with excitation
wavelength of 480 nm and emission wavelength of
590 nm. The excitation and emission slit width
were set to 1.00 mm and data were collected at
0.1-s intervals. After 100 s, the detection was
paused, 1 mM Mg2+ and 1 mM ATP, pH7.5 were
added into the reaction and the detection was
continued for additional 400 s. Where indicated,
ATP was substituted with 1 mM GTP or 5 mM
NADH. The rate of Dox transport was determined
from the slope of the initial linear range between

and the UV probe 2. 20 Kinetics software. The
slope of the linear portion of each curve (between
200 s and 400 s) was used to calculate ATPase
activity. The activity of the control IOVs (without
DrrAB) was subtracted from the activity of each
test sample to obtain DrrAB-specific activity.
Relative activity was then calculated by dividing
the activity of each sample by the activity of the
wild type sample.
RESULTS
Characterization of the DrrAB-mediated
Dox efflux under in vivo and in vitro conditions –
An in vivo assay for studying DrrAB-mediated
Dox efflux was reported previously (18,21) and is
shown in Fig. 1A. In this study, we established
conditions to study DrrAB-mediated Dox efflux
under in vitro conditions using E. coli inside out
membrane vesicles (IOVs) (Fig. 1B). Both in vivo
and in vitro assays utilize the fluorescent nature of
Dox to measure efflux in E. coli LE392ΔuncIC
cells (or IOVs). This strain of E. coli contains a
deletion in the unc genes; as a result it is unable to
carry out synthesis of ATP using proton gradients
or establish a proton gradient by hydrolysis of
ATP (22). Therefore, it is possible to establish
conditions where only the proton motive force
(pmf) or ATP is available as a source of energy
(described below). Dox is fluorescent in solution,
however its accumulation inside the cells results in
quenching of its fluorescence and its efflux results
in an increase in fluorescence intensity (23).
In vivo Dox efflux – The basic strategy for
studying efflux under in vivo conditions consists
of loading of the de-energized cells with Dox (18),
followed by addition of an energy source, which is
expected to result in efflux of Dox and an increase
in its fluorescence (Fig. 1A). Under the conditions
used in our experimental system, use of succinate
as energy will generate only proton motive force
while glucose will generate both pmf and ATP,
therefore allowing us to discriminate between the
energy sources used by the DrrAB system. The
data in Fig. 1A compare the rate of Dox efflux in
DrrAB-containing cells in the presence of glucose
or succinate.
E.coli LE392ΔuncIC cells
(containing empty vector) were used as negative
control in these experiments. Two conclusions
can be made from the data shown in Fig. 1A. First,
the rate of Dox efflux by the DrrAB-containing
5
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of Dox efflux by H 33342, four different
concentrations of Dox (0.25, 0.5, 0.75 and 1.0 µM)
were individually mixed with a fixed
concentration of H 33342 in 1x PBS buffer
containing 250 µg IOVs, 0.1 mg/ml creatine
kinase and 5 mM creatine phosphate. In total, four
different concentrations of H 33342 (0, 0.2, 0.6 or
0.8 µM) were studied. Similar assays were set up
to study kinetics of Dox inhibition by different
drugs.
Initial rate of Dox transport was
determined, as described above. The rate of Dox
transport obtained with 1 µM Dox and 0 µM H
33342 (or another drug) was designated as 1.0.
The relative rates were then calculated for each
efflux curve, and the data were plotted by
Lineweaver-Burk plot using SigmaPlot - Kinetics
software in Single-Substrate/Single-Inhibitor
Kinetics Format. The error bars represent three
independent experiments. The type of inhibition
was determined based on the AICc value (Akaikes
Information Criterion corrected); lower AICc
values correspond to better fits to the data.
Point Mutations in DrrA – Site-directed
mutagenesis of the drrA gene was carried out by a
QuikChange Multisite-directed mutagenesis kit
(Stratagene, La Jolla, CA). Using pDX101
(pSU2718/drrAB) plasmid as the template, Gln197,
located in the Switch motif of DrrA, was changed
to Histidine. The resulting plasmid was named
pDX101(Q197H). Another plasmid, generated by
substituting Tyr198 to Arginine, was named
pDX101(Y198R).
Double mutations of
Gln197Tyr198
to
His197Arg198
and
His197His198 were also created, and these
plasmids were named pDX101(Q197H/Y198R;
HR) and pDX101(Q197H/Y198H; HH). Other
mutations used in this study were described
previously (Table 1).
ATPase activity in IOVs - 7.5 µg IOVs
expressing either wild type DrrAB or DrrAB with
mutations in the Switch motif were incubated in 1
ml reaction mixture containing 50 mM MOPs, pH
7.5, 1mM dithiothreitol, 10µl PK/LDH enzyme
(Sigma Aldrich), 5 mM ATP, 0.25 mM NADH (βNicotinamide adenine dinucleotide) and 1.25 mM
PEP[phosphor(enol)pyruvic acid] at 37 ºC for 10
min, as described previously (20). The reaction
was started by addition of 2.5 mM MgCl2. The
optical density at 340 nm was monitored for 10
min using Shimadzu UV1601 spectrophotometer

(column 2) or ATP (column 3) resulted in the
failure of these vesicles to transport Dox. Use of
NADH as an energy source also did not support
Dox efflux (column 6), once again confirming that
proton motive force is not used by the DrrAB
proteins as a source of energy. Surprisingly, when
GTP was used as an energy source instead of ATP,
even higher transport activity was observed
(column 5).
Dox-dependent ATP and GTP
binding to DrrA was shown previously (17).
Together these data indicate that either ATP or
GTP (and Mg2+) can serve as a source of energy
for the Dox transport function of DrrAB.
Kinetic Analysis of Dox efflux in vitro –To
understand the kinetics of Dox efflux by the
DrrAB system, efflux was analyzed (as shown in
Fig. 1B.1) at a wide range of Dox concentrations.
The initial rate (slope between 100 s-200 s) of
each efflux curve was determined. Efficiency of
Dox efflux was then calculated, as described under
Methods and Figure Legends. The data were
fitted to a hyperbola using the Michaelis-Menten
equation (with an R2 of 0.89), yielding an apparent
Km of 0.38 µM and Vmax of 1003 (arbitrary units,
a.u.) (Fig. 1C). These data showed a linear
increase in the rate of Dox transport at
concentrations ranging between 0.1 µM and 1 µM,
which became saturated after 3µM. The Dox
transport data could also be fitted equally well by
the Hill equation; the implication of this finding is
discussed later.
Inhibition of Dox transport activity by
sodium o-vanadate – Vanadate (Vi) is a known
inhibitor of the ATPase activity of ABC proteins
(26-29). Since it functions as an analog of Pi, the
ADP·Vi·Mg2+ complex is trapped in the ATP
binding pocket after a single catalytic turnover,
thus blocking further hydrolysis of ATP as well as
drug transport. To determine if the DrrAB system
is inhibited by vanadate, Dox transport was
measured in IOVs in the absence or presence of
increasing amounts of vanadate (5 µM to 100 µM).
The data in Fig. 1D show that vanadate is a potent
inhibitor of the Dox transport of DrrAB, with an
IC50 = 11 µM. A complete inhibition of the Dox
transport activity was seen at 100 µM vanadate.
These data are consistent with the previously
reported studies on the inhibitory effect of
vanadate on Pgp and MsbA (28,30).

6
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cells in the presence of glucose is about 5-fold
higher as compared to the rate in control cells (Fig.
1A.2, compare columns 1 and 4). A small increase
in Dox efflux efficiency seen in control cells on
addition of glucose is likely due to the action of
one of the several MDR pumps known to be
present in E. coli (1). Secondly, in contrast to
glucose, use of succinate as energy showed no
increase in fluorescence intensity in DrrABcontaining cells (Fig. 1A.1, curve 2; Fig. 1A.2,
column 2), indicating that pmf does not support
Dox efflux by the DrrAB proteins. Confirmation
of these results was obtained by addition of
sodium fluoride, a specific inhibitor of ATP
synthesis by substrate-level phosphorylation, to
DrrAB-containing cells in the presence of glucose.
The data show a drastic reduction in Dox efflux by
the DrrAB-containing cells (Fig. 1A.1, curve 3;
Fig. 1A.2, column 3), resulting in the same
background levels of efflux as seen with succinate
(column 2). These studies show that doxorubicin
efflux by the DrrAB pump is solely ATPdependent, and pmf is not required for this process,
thus highlighting similarities between DrrAB and
other MDR proteins of the ABC superfamily
(19,24,25).
In vitro Dox efflux – To understand the
kinetics of Dox transport, an in vitro Dox efflux
assay was optimized using inside-out membrane
vesicles, as described under Methods. In this
assay, the vesicles were mixed with Dox, and
efflux was initiated by addition of ATP and Mg2+.
Because of the inverted nature of the IOVs,
DrrAB-mediated efflux results in accumulation of
Dox inside the vesicles which is seen as quenching
of its fluorescence (Fig. 1B.1). The data in Fig.
1B.1 show that addition of ATP/Mg2+ first results
in a rapid non-specific decrease in Dox
fluorescence due to interaction between Dox and
ATP (23). This quick phase is then followed by a
slower rate of quenching, which corresponds to the
DrrAB-dependent efflux in the vesicles. The
initial rate of Dox efflux was therefore determined
from the linear slope of the fluorescence spectra
between 100 s and 200 s. As seen in Fig.1B.1 and
1B.2, Dox transport activity in vesicles containing
DrrAB was found to be almost 12-fold higher as
compared to the control vesicles prepared from
cells containing vector alone (Fig. 1B.2, compare
columns 1 and 4). Absence of either Mg2+

7
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contain an HH sequence in the Switch region (Fig.
2A.3), and both prokaryotic and eukaryotic
homologs contain the conserved glutamate in the
Walker B region (specifically E165 in DrrA) (Figs.
2A.2 and 2A.3)
Since histidine is conserved in the Switch
of most ABC proteins, we wondered if the DrrAB
transporter will become more efficient if Q197 is
substituted with a histidine or if the QY sequence
is changed to the commonly occurring sequence
HR or HH. Surprisingly, we found that the
Q197H mutation in DrrA produces a drastic effect
on Dox efflux, however mutation of Y198 to
Y198R retains about 35% Dox efflux function
(Fig. 2C). Interestingly, a double mutation HR
(Q197H/Y198R) also resulted in Dox transport
activity of about 38% indicating that the second
mutation partially masked the harmful effect of the
Q197H single mutation (Fig. 2C). By contrast, the
double mutation HH (Q197H/Y198H) exhibited
extremely low Dox efflux (Fig. 2C).
To
understand the role of Q197 and Y198 in catalysis,
the effect of the above-mentioned mutations on the
ATPase activity of the DrrAB complex was
determined.
We found that while Q197H
produces a drastic effect on ATPase activity, both
HR and HH double mutations show significant
ATPase activity (43% and 61%, respectively)
(Figs. 2D and 2E), indicating that the second
mutation in each case partially compensates for
the negative effect of the Q197H mutation on
catalysis. Overall the findings in Fig. 2 indicate
that residues Q197 and Y198 in the Switch motif
of DrrA function together and that the QY
sequence works much better than the HH or HR
sequence for the overall Dox efflux function of the
DrrAB complex. Interestingly, the HH double
mutant still exhibits 60% ATP hydrolysis activity,
which suggests that either the QY or the HH
sequence could participate in the formation of
functional catalytic sites in DrrA. However, the
HH allele seems to be defective in specific
communication between DrrA and DrrB resulting
in significantly reduced Dox efflux (less than 5%).
Therefore the context in which the Switch motif
functions in different ABC proteins may determine
the nature of this motif. The conserved glutamate
E165 present near the Walker B region in DrrA
served as a control in these experiments. Analysis
of the E165Q mutation showed a drastic effect on

Point mutations in the nucleotide binding
domain (NBD) of DrrA compromise Dox
transport activity – The N-terminal nucleotide
binding domain of DrrA contains a 200 amino
acids long ABC cassette consisting of all the
conserved motifs (Walker A, Walker B, Signature
motif/C-loop, Q-loop, and the Switch motif/Hloop) involved in ATP binding and hydrolysis (Fig.
2A.1). We previously reported that mutations in
the conserved residues of DrrA confer Dox
sensitivity (31). Mutations in Walker A, as
expected, also compromised ATP binding (31).
Here we evaluated the effect of several mutations
on DrrAB-mediated Dox efflux in IOVs. The data
in Fig. 2B show that, as expected, single point
mutations in Walker A (such as G44A, G44S or
K47R), signature (S141R), or the Walker B
(E165Q) motif of DrrA result in a drastic effect on
Dox transport activity. Since the sequence of the
Switch motif of DrrA is different from most other
ABC proteins (Fig. 2A), this region was analyzed
in greater detail, as described below. Most ABC
proteins normally contain a highly conserved
histidine residue in their Switch motif, followed by
an arginine, histidine, or a lysine (Fig. 2A.1). The
conserved histidine of the Switch motif and a
conserved glutamate immediately following the
Walker B motif (both are shown as highlighted
areas in Fig. 2) are together believed to be critical
for formation of the active sites in ABC proteins.
Zaitseva et al recently proposed that these two
residues together form a catalytic dyad which
functions in substrate-assisted catalysis (32).
However, despite the high conservation of these
two residues in ABC proteins, deviations in the
sequence of these motifs are sometimes seen.
Most commonly, a glutamine replaces the
histidine in the Switch motif and an aspartate
replaces the glutamate in the Walker B region.
When present (for example, in TAP1 and LmrC),
these deviations are seen to result in asymmetrical
ATP binding pockets with one site being
catalytically non-functional (33,34). Interestingly,
however, despite the presence of the noncanonical glutamine residue (Q197 followed by
Y198, resulting in QY sequence) in the Switch
motif of DrrA (and its close prokaryotic homologs,
Fig. 2A.2), it is able to form a functional drug
transporter with DrrB, as seen in Fig. 1. Note that
the close eukaryotic homologs of DrrA most often

much higher concentrations of EtBr, quinidine,
and colchicine were required for the same level of
inhibition. These data suggest that the DrrAB
system has multiple substrates, which bind with
varying affinities. However, whether these drugs
bind to the same site, or if there are multiple drug
binding sites, can’t be ascertained from these data.
To understand the nature of drug binding, kinetics
of DrrAB-mediated Dox efflux was studied at
multiple Dox concentrations in the presence of
several concentrations of each inhibitory drug,
which is described below.
Kinetics of Dox Inhibition by MDR drugs
– The data in Fig. 1C showed that the rate of Dox
efflux by DrrAB-containing IOVs increases
linearly between 0.1 µM and 1 µM Dox
concentration, therefore four evenly distributed
concentrations of Dox within this range (0.25, 0.50,
0.75, and 1.0 µM) were used in the kinetics
analysis. At each concentration of Dox, efflux
was measured in the presence of our different
concentrations of H 33342, verapamil, or
rifampicin. These drugs were chosen based on
their low IC50 values seen in inhibition studies
(Fig.3D). (Since Dox and EtBr together were
incompatible in the fluorescence-based assays due
to their overlapping excitation/emission spectra,
this combination could not be used in this study).
The initial slope (100-200 seconds) for each Dox
efflux curve was determined. The slope of the
Dox efflux curve at 1.0 µM Dox and 0
concentration of the inhibitor was designated as 1,
which was then used to calculate the relative slope
of each curve obtained in the presence of the
inhibitor, as described under Methods. The relative
slopes were plotted by the Lineweaver-Burk plots
using the Sigma Plot kinetics software (Fig. 4).
The data in Fig. 4A indicate that the inhibition of
Dox efflux by H 33342 is characteristic of
competitive inhibition; the Km of DrrAB-mediated
Dox
transport
increased
at
increasing
concentration of H 33342, whereas the Vmax
remained unchanged. These data suggest that Dox
and H 33342 may bind to the same site in DrrAB.
The apparent inhibition constant (Ki for H 33342)
was found to be 0.64 µM, which corresponds well
to the IC50 value of H 33342 (Fig 3, panel D).
When studying the inhibition of Dox transport by
rifampicin, a similar pattern was observed, which
indicated a competitive inhibition between Dox
8
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both hydrolysis of ATP and Dox efflux (Figs. 2BD), which is consistent with the critical role of this
residue previously reported in literature (35). How
a glutamine residue participates in the formation
of functional ATP binding pockets in DrrA is still
an open question. However, we can draw from the
analogous situations present in other ATP/GTPbinding proteins (including RecA and H-ras p21)
which contain a catalytic glutamine residue (Q194
in RecA and Q61 in H-ras p21) in their switch II
domain in the position corresponding to Q197 in
DrrA (36-38). The 3-d structures of RecA and Hras indicate that these glutamines show similar
interactions with the catalytic glutamate and γ
phosphate of ATP to those seen with histidine in
the ABC proteins, therefore suggesting that the
glutamine functions in a manner similar to
histidine in producing the overall conformation of
the active site. This is consistent with our
observation that either QY or HH sequence can
indeed participate in formation of the catalytic
sites in DrrA although the HH sequence is
deficient in energy transduction. In summary, the
analyses in Fig. 2 confirm that a functional
nucleotide binding domain of DrrA is essential for
Dox efflux by the DrrAB system. The analysis of
the Switch mutations, in particular, also indicates
that the in vitro efflux assay described here can
provide a sensitive and a valuable approach for
elucidating the role of critical residues in the
catalytic and drug transport function of the DrrAB
complex.
DrrAB-mediated Dox efflux is inhibited
by multiple MDR substrates – To determine if the
DrrAB transporter can recognize and bind other
known MDR substrates, inhibition of Dox efflux
by different drugs was investigated in IOVs.
These assays were carried out at a wide range of
the inhibitor concentrations while maintaining a
constant concentration of Dox, as described under
Methods (determination of IC50 values). The data
in Fig. 3 show that many known MDR drugs,
including H 33342 (Fig. 3A), verapamil (Fig. 3B),
and rifampicin (Fig. 3C), inhibit DrrAB-mediated
Dox efflux with high efficiency. The data in Fig 3,
panel D, summarize the inhibitory effects of many
different MDR substrates and indicate that the IC50
values vary dramatically for different substrates.
For example, H 33342, vinblastine, verapamil and
rifampicin show relatively low IC50 values, while

analyzed at a wide range of concentrations. The
initial rate of H 33342 transport in DrrABcontaining IOVs was measured between 0.1 µM
and 2.5 µM (Fig 5A.2). The efficiency of H
33342 transport was calculated, as described
earlier for Dox (Fig. 1C). The data were plotted
using the Michaelis-Menten equation by the Sigma
Plot kinetics software and could be fitted to a
hyperbola with an R2 of 0.90, yielding an apparent
Km of 0.78 µM and Vmax of 16000 (a.u.). To study
kinetics of EtBr transport, energy-depleted cells
were loaded with different concentrations of EtBr
(ranging from 1 µM to 100 µM) for 1 hour, and
efflux was initiated by addition of 20 mM glucose
(Fig 5B.2). The data fitted to the hyperbola
(Michaelis-Menten equation) with an R2 of 0.97,
yielding an apparent Km of 21µM and Vmax of 550
(a.u.). The data in Fig 5 show that both H 33342
and EtBr are transported efficiently by the DrrAB
system. A comparison of the Km and Vmax values
for transport of Dox, H 33342, and EtBr is shown
in Fig 5, panel C. Five other fluorescent substrates
(Hoechst 34580, Hoechst 33258, quinine,
tetramethylrhodamine (TMRM), and Rhodmine
123) tested in this study were not found to be
exported by the DrrAB system (data not shown).
In general, the transport data agreed with the
inhibition data shown in Fig. 3, panel D.
Interestingly, of the three Hoechst dyes tested,
only H 33342 was transported. Recent studies
showed that a certain balance between the
hydrophobic and hydrophilic forces in the
structure of the target substrate is essential for
optimum efflux by Pgp (39). Since H 33342 is the
most amphiphilic of the three dyes, this may
explain why DrrAB is able to preferentially
transport H 33342 but not the other two dyes.
DISCUSSION
Multidrug resistance is conferred by the
action of specialized proteins in the cell membrane
that have the ability to carry out energy-dependent
efflux of structurally and functionally unrelated
hydrophobic compounds.
This phenomenon
defies the concept of single enzyme-single
substrate (the lock and key model), which is
applicable to most other enzymes. Since the
discovery of multidrug resistance in human cancer
cells and bacteria (40-42), two important questions
have remained at the forefront of this field: 1)
what is the basis of poly-specific drug recognition
9
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and rifampicin (Fig. 4C). However, the kinetics of
inhibition of Dox transport by verapamil showed a
different pattern (Fig. 4B). The Vmax decreased at
increasing concentration of verapamil, while Km
remained unaltered, indicating a non-competitive
inhibition between Dox and verapmail. These data
suggest that verapmail may bind to both the
unliganded DrrAB and the binary DrrAB-Dox
complex. The Ki value for verapamil inhibition
was found to be 9.4 µM, which also matches well
to the IC50 of verapamil (Fig. 3, panel D). The
observed competitive and non-competitive
inhibitions of DrrAB-mediated Dox transport in
IOVs imply that DrrAB must contain at least two
drug binding sites.
The DrrAB system is a multidrug
transporter – To determine whether the DrrAB
system can actually transport other drugs in
addition to Dox, two substrates (H 33342 and EtBr)
commonly used to establish the MDR phenotype
(10,19), were tested in IOVs, as described under
Methods. In addition, five other fluorescent dyes
or drugs (including Hoechst 34580, Hoechst
33258, quinine, TMRM, and Rhodmine 123) were
also tested. Of these substrates, H 33342 and EtBr
were successfully transported by the DrrAB
system, as described below.
H 33342 is a cell-permeable dye, which is
fluorescent only when bound to the cell membrane
and loses its fluorescence in aqueous environment.
Thus a decrease in fluorescence is expected when
H 33342 is transported by the DrrAB system from
the membrane to the inner aqueous environment in
the IOVs. EtBr, on the other hand, becomes
fluorescent when bound to DNA inside the cells.
Therefore, DrrAB-mediated efflux of EtBr was
studied in preloaded cells, as described under
Methods. EtBr efflux under this condition is
expected to result in quenching of fluorescence.
The data in Fig. 5 show that both H 33342 (Fig
5A.1) and EtBr (Fig 5B.1) are transported
efficiently by the DrrAB system. In the case of H
33342, the rate of transport was seen to decrease
after an initial linear phase of transport. This is
likely due to depletion of H 33342 in the
membrane and due to passive rebinding of H
33342 to the membrane from the aqueous phase,
as shown earlier in the case of Pgp (19). To
determine the kinetic parameters for the transport
of H 33342 and EtBr, efflux of each substrate was

antibiotic producing organisms contain dedicated
export systems to protect themselves against their
own antibiotics (56,57). Understanding these
systems could hold the key to unraveling the
origin and evolution of multidrug specificity. It is
generally assumed that the dedicated systems
found in producer organisms belong to the
category of single-drug transporters as opposed to
multi-drug transporters (2), however their
substrate specificity has never been investigated in
any significant detail thus providing the impetus
for this study.
We show for the first time that the DrrAB
system functions as a typical multidrug transporter
that can carry out efflux of structurally unrelated
substrates, including Dox, EtBr and H 33342.
Inhibition studies further demonstrate that the
substrate range of the DrrAB system includes
many additional substrates, such as verapamil,
vinblastine, and rifamicin, among others. Thus the
substrate specificity of DrrAB overlaps with most
other known MDR proteins, including Pgp (5860). We found, however, that unlike Pgp, neither
quinine nor rhodamine 123 serve as substrates for
export by the DrrAB system nor did they show
inhibition of Dox transport. Therefore, in spite of
the broad substrate range of DrrAB, it appears that
the range of substrates recognized by Pgp may still
be larger (61), implying that the ability to bind
some of these substrates may have evolved later in
Pgp.
Interestingly, the IC50 values varied
significantly among different drugs, indicating the
different binding affinities of each substrate. The
highest IC50 was observed for colchicine, which is
consistent with the data previously reported for
Pgp (47,62,63). This may be related with low
hydrophobicity of colchicines (64), therefore
indicating that the ability to partition into the
membrane may be an important factor for
transport by both Pgp and DrrAB.
Kinetic characterization of Dox, H 33342,
and EtBr transport by the DrrAB system revealed
single-site transport kinetics. Further, the Km
values of 0.38 µM and 0.78 µM for transport of
Dox and H 33342, respectively, reflect high
affinity of these substrates for the DrrAB system
and correspond well with the Km values seen
earlier for Dox transport by Pgp (65) and H 33342
transport by MsbA and LmrA (10). Interestingly,
however, we found that the kinetic data for Dox as
10
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and transport by MDR proteins? 2) How and why
does MDR evolve?
Extensive biochemical
analysis of Pgp (1,4,5) as well as the availability
of three-dimensional structures of the drug-bound
forms of Pgp, AcrB, BmrR and QacR (6,8,43,44)
has contributed significantly to understanding the
molecular basis of poly-specific drug binding.
These studies indicate that the MDR proteins
contain an extensive (and flexible) drug binding
pocket which can accommodate multiple drugs
simultaneously via interactions with specific
(sometimes overlapping) aromatic and polar
residues present in different parts of the pocket.
The 3-D structure of Pgp, in particular, also
provides support for the hydrophobic vacuum
cleaner model, which was proposed early on by
Gottesman and colleagues (7,15) to explain the
mechanism of multidrug transport. According to
this model, Pgp substrates (which are primarily
cationic, lipid soluble, planar molecules) partition
spontaneously into the membrane and are picked
up by Pgp directly from the membrane (instead of
from the cytoplasm) and then removed by its
ability to flip drugs from the inner to the outer
leaflet. This model, which has now been extended
to many other MDR proteins (45), makes a clear
distinction between the classical solute
transporters that remove molecules from an
aqueous compartment and the MDR proteins that
are proposed to function as flippases (46). A clear
relationship between the ability of drugs to
partition into the membrane and their binding and
transport by Pgp has since been documented (4749). Additional evidence in support of this model
comes from 1) the ability of most MDR proteins
studied to date to extrude the lipopilic dye H
33342 directly from the membrane (3,19,50,51),
thus making it an ideal molecule to establish the
MDR phenotype and 2) the ability of many MDR
proteins to flip-flop lipids (52-55). Together,
these observations led to the idea that hydrophobic
drugs and lipids may use a common pathway or
flipping mechanism for extrusion.
Despite
significant
progress
in
understanding the basis of poly-specific drugbinding, the origin of multidrug resistance still
remains an enigma. It is generally accepted that
most of the antibiotic and drug resistance genes
found in clinical settings have their origins in the
environmental bacteria (1).
Indeed many

flippase action? Doxorubicin is produced inside S.
peucetius cells, therefore presumably the function
of the DrrAB system is to remove it from the
cytoplasmic compartment to the outside. Being
amphipathic, however, Dox could conceivably
partition into the cell membrane and then be
picked up by the DrrB protein directly from the
membrane, as suggested in an early model
proposed for AcrB function (8). This strategy for
its removal could also provide protection to the
cell from the toxic effects of free Dox inside the
cell. The ability to transport H 33342 no doubt
indicates that the DrrB protein can indeed extract
this fluorescent dye directly from the membrane
by a mechanism similar to the one used by Pgp
and other proteins (10,19,60). Future studies will
therefore focus on an in-depth analysis of the
mechanism of drug extrusion by the DrrAB
system.
This and previous studies on MDR
proteins raise many other intriguing questions; for
example, is there evolutionary relatedness between
MDR proteins and lipid flippases? What is the
real difference between the single-drug and multidrug transporters? What makes certain proteins
specific for a substrate and some others multispecific?
What is the contribution of high
aromatic amino acid content of the TM helices of
MDR proteins in conferring poly-specificity?
Since the transmembrane helices of Pgp and other
MDR proteins, such as the bacterial BMR, are
highly enriched in aromatic amino acids (18% and
15.4% for Pgp and BMR, respectively) as
compared to the single-drug transporter TetA
(9.4%), Pawagi et al. proposed that a greater
number of aromatic amino acids may correlate
with a decrease in substrate specificity of a
transporter by providing additional binding sites
for drugs containing aromatic rings in their
structure (69). Moreover, it was shown that
mutagenesis of a single residue Ser941 to Phe in
TM11 of Pgp significantly altered its drug efflux
profile (70). The recent 3-D structure confirmed
that the drug-binding pocket of Pgp is made up of
mostly hydrophobic and aromatic residues (6).
Interestingly, we found that the aromatic amino
acid content of predicted TM helices of DrrB (71)
is also relatively high (15%) which is close to the
aromatic content of Pgp (18%) and BMR (15.4%).
Whether this plays a role in conferring multi11
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well as H 33342 could also be fitted by the Hill
equation (shown in Fig. 5C) providing the nHill
value of 1.7 for Dox (R2 = 0.93) and 2.0 for H
33342 (R2 = 0.95), which suggests co-operative
interaction between two or more drug binding sites
in DrrAB. It is not clear from these data, however,
whether both H 33342 and Dox bind to the same
sites in the DrrAB system. Since EtBr transport
by DrrAB exhibited only single-site transport
kinetics (nHill=1.1; R2 = 0.98) (Fig. 5C), it possibly
interacts with only one of the Dox/Hoechst
binding sites, or it may bind to a completely
different site in DrrAB. The kinetic analyses
shown in Fig. 4 provide evidence for competitive
inhibition of Dox transport by H 33342 and
rifampicin and non-competitive inhibition by
verapamil. Therefore, we conclude that both H
33342 and rifampicin bind to the same site(s) as
Dox, whereas verapamil may bind to a different
site in DrrAB. Evidence for two or more nonidentical drug binding sites has also been obtained
previously with MsbA (10,53), LmrA (25) and
Pgp (10,66,67). In Pgp, the two sites were defined
as the H and R sites based on their preferential
binding to H 33342 and Rhodamine, respectively
(68). Together, these data point towards the
presence of two or more drug binding sites in the
DrrAB system. Gleaning from the knowledge
previously gained from studies with Pgp and
AcrB, these different drug binding sites are likely
part of the same binding pocket in DrrB.
However, in the absence of a crystal structure of
the DrrAB transporter, this conclusion is only
tentative.
Even though the present study does not
provide an answer to the origin of poly-specific
drug recognition, it does indeed show that a simple
system like DrrAB (which may be closely related
to the ancestral system) already contains the
ability to recognize and transport multiple
substrates. This leads us to conjecture that the
ability to transport multiple drugs is an inherent
property of a certain class of proteins that followed
a different evolutionary path than the classical
transporters. This work also opens new questions
regarding the mechanism by which the DrrAB
system extrudes multiple hydrophobic substrates.
The most important of these questions is whether
this system relies on a hydrophobic vacuum
cleaner-like mechanism and if it is capable of

specificity in DrrB will be determined in future
studies by mutagenesis of specific aromatic and

other residues in DrrB.
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FIGURE 1. Characterization of the DrrAB-mediated Dox efflux under in vivo and in vitro
conditions. (A) In vivo analysis of DrrAB-mediated Dox efflux using E. coli cells. E. coli
LE392ΔuncIC cells containing either vector or pDX101 (DrrAB) were loaded with 10 µM Dox, and the
whole cell Dox efflux assay was performed, as described under Methods and in ref (21). Dox efflux was
measured fluorometrically (exi, 480 nm; emi, 590 nm) on an Alphascan-2 spectrofluorometer (Photon
Technology International). Energy was provided in the form of 20 mM glucose or 20 mM succinate at
100 seconds (marked with an arrow) and fluorescence was monitored for an additional 400 seconds. 10
mM sodium fluoride (NaF) was added to the samples, where indicated. A.1: Curve 1,
pDx101(DrrAB)/glucose; Curve 2, pDx101 (DrrAB)/succinate; Curve 3, pDx101 (DrrAB)/glucose/NaF;
Curve 4, pSU2718 (vector)/glucose; Curve 5, pSU2718/succinate; Curve 6, pSU2718/glucose/NaF. A.2:
Quantitative presentation of the Dox efflux data shown in Fig 1A.1. The slope of the linear portion of
each curve shown in Fig 1A.1 was calculated. The slope of curve 1 was designated as 1.0. Relative slope
of each curve was then obtained by dividing the slope of the curve by the slope of curve 1. The average
data obtained from three independent experiments are shown in the histogram. (B) In vitro analysis of
DrrAB-mediated Dox efflux using inside-out membrane vesicles (IOVs). E. coli LE392ΔuncIC cells
containing either vector or pDX101 (DrrAB) were grown to mid-log phase and induced with 0.25 mM
IPTG at 37 °C for 3 hr. The membrane fraction was prepared (14) and Dox efflux in DrrAB-containing
IOVs was performed, as described under Methods. B.1: In vitro Dox efflux assay was carried out using
250 µg IOVs in the presence of 1 µM Dox, 0.1 mg/ml creatine kinase and 5 mM creatine phosphate in 3
ml PBS buffer, pH 7.5, as described under Methods. Vector, Dox efflux in IOVs prepared from cells
containing empty vector; DrrAB, Dox efflux in IOVs prepared from cells containing pDX101 (DrrAB).
B.2: Quantitative presentation of Dox efflux in DrrAB-containing IOVs under various conditions.
In vitro Dox efflux assay was carried out in the presence or absence of 1 mM ATP, 1mM GTP, 1 mM Mg
or 5 mM NADH, as described under Methods. The initial rate of Dox efflux was determined from the
linear slope of the fluorescence spectra between 100 s and 200 s. The slope of the efflux curve obtained
by incubation of the DrrAB-containing IOVs with ATP and Mg2+ (column 4) was designated as 1.0. The
relative slope for each curve was then calculated by dividing the slope of the curve by the slope of sample
4. The average data obtained from three independent experiments are shown in the histogram. (C)
Kinetic analysis of DrrAB-mediated Dox efflux in IOVs. In vitro Dox efflux was analyzed using 250
µg IOVs in the presence of increasing concentrations of Dox (0.1 µM to 6.0 µM) and 1 mM ATP/Mg2+.
The initial linear rate of Dox efflux was determined for each curve. The data obtained from three
independent experiments were fitted to the Michaelis-Menten equation and plotted by SigmaPlot-Kinetics
software using the equation for Single Substrate Format. (D) Inhibition of DrrAB-mediated Dox efflux
by sodium o-vanadate. In vitro Dox efflux was measured using 250 µg IOVs in the presence 1 µM Dox,
1 mM ATP and 1 mM Mg2+ and increasing concentrations of Vi (0 – 100 µM). The initial slope of the
efflux curve obtained with 0 µM Vi was designated as 1.0. The relative slope of each curve was

determined, as described under panel A.2.
experiments are shown in the histogram.

The average data obtained from three independent

FIGURE 3. Inhibition of the DrrAB-mediated Dox efflux by known MDR substrates. Dox efflux
was measured using 250 µg IOVs in the presence 1 µM Dox and increasing concentrations of the
inhibitory substrate in 3ml PBS, pH 7.5. The initial linear rate (100 s - 200 s) of Dox efflux was
determined after addition of 1mM ATP/Mg2+. The slope of the efflux curve obtained at 0 concentration
of inhibitor was designated as 1.0. The relative slope of each curve was then determined. The average
slopes resulting from three independent repeats were plotted by Sigma Plot software using ‘scatter plot
with error bars’, and IC50 values were determined. (A) Kinetic analysis of the inhibitory effect of H
33342 on Dox efflux activity. The experimental conditions were the same as described above. The
assay was carried out in the presence of increasing concentrations of H 33342 ranging from 0 – 1.6 µM.
(B) Kinetic analysis of the inhibitory effect of verapamil. The experimental conditions were the same
as for Fig. 3(A), except that the concentration of verapamil ranged from 0 µM to 100 µM. (C) Kinetic
analysis of the inhibitory effect of Rifampicin. The experimental conditions were the same as for Fig.
3(A), except that the concentration of rifampicin ranged from 0 µM to 75 µM. (D) A table showing
summary of the IC50 values. Kinetic analysis of the inhibitory effect of various drugs on DrrABmediated in vitro Dox efflux was determined, as described above for panels 3A-C. The IC50 values were
calculated as described under Methods.
FIGURE 4. Kinetic characterization of the inhibition of DrrAB-mediated Dox efflux by H 33342,
verapamil or rifampicin. The kinetics of DrrAB-mediated Dox efflux was determined in the presence of
fixed concentrations of inhibitor, as shown in panels 4A-C. (A) Competitive inhibition by H 33342.
DrrAB-mediated Dox efflux was studied at four different concentrations of Dox (0.25, 0.5, 0.75 and 1.0
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FIGURE 2. Effect of point mutations in the NBD of DrrA on DrrAB-mediated Dox efflux in IOVs.
(A) ClustalW alignment of the NBD of DrrA and its prokaryotic or eukaryotic homologs. The
conserved motifs present in the NBD are marked at the top. A.1, alignment of the NBD of DrrA with
proteins (MalK, Sav1866, HlyB, TAP1, TAP2, LmrC, LmrD and LmrA) from diverse ABC families.
A.2, alignment of the NBD of DrrA with close prokaryotic homologs (belonging to the DRA family/DRR
subfamily) (16) identified by NCBI BLAST. A.3, alignment of the NBD of DrrA with close eukaryotic
homologs belonging to the DRA family/ABCA subfamily (16). (B) Effect of point mutations in Walker
A, Walker B, or the Signature motif of DrrA on DrrAB-mediated Dox efflux in IOVs. E. coli
LE392ΔuncIC cells containing either pSU2718 vector, pDX101 (drrAB in pSU2718), pDX102 (drrA
only, in pSU2718), pDX103 (drrB only, in pSU2718) or pDX101 containing mutations of Walker A
(G44A, G44S, K47R), Signature motif (S141R), or the Walker B region (E165Q) were induced with
IPTG, and the IOVs were prepared, as described under Methods. The initial rate of Dox efflux was
determined for each sample, and the relative slopes were calculated, as described for Fig. 1. The average
data obtained from three independent experiments are shown in the histogram. (C) Effect of point
mutations in the Switch motif of DrrA on DrrAB-mediated Dox efflux in IOVs. E. coli
LE392ΔuncIC cells containing either pSU2718 vector, pDX101 (drrAB in pSU2718), or pDX101 with
mutations of the Walker B region (E165Q) or the Switch motif (Q197H, Y198R, Q197H/Y198H,
Q197H/Y198R) were induced with IPTG, and the IOVs were prepared, as described under Methods. The
initial rate of Dox efflux was determined for each sample, and the relative slopes were calculated, as
described for Fig. 1. The data presented are averages of three independent experiments. Error bars
represent standard deviation. (D) Effect of point mutations in the Switch motif of DrrA on DrrABmediated ATPase activity in IOVs. IOV samples from Fig. 2(C) were subjected to the NADH-coupled
ATPase activity assay, as described under Methods. The relative ATPase activity of each sample was
obtained by dividing the activity of each sample by the activity of wild type. The data presented are
averages of two independent experiments. Error bars represent standard deviation. (E) Summary of the
ATPase activity and Dox efflux activity of wild type DrrAB and Switch motif mutants.

µM) in the presence of a fixed concentration of H33342. In total, four different concentrations of H
33342 (0, 0.2, 0.6, 0.8 µM) were studied. The rate of Dox transport obtained with 1 µM Dox and 0 µM H
33342 was designated as 1.0. The relative rates were then calculated for each efflux curve, and the data
were plotted by Lineweaver-Burk plot using Sigma Plot- Kinetics software in Single Substrate – Single
Inhibitor Kinetics Format. The error bars represent three separate experiments. The type of inhibition
was determined based on the rank of both AICc and R2. (B) Non-competitive inhibition by verapamil.
The experiment was performed as described under panel (A). Four different concentrations of verapamil
(0, 3.5,7, 14 µM) were used. (C) Competitive inhibition by rifampicin. The experiment was performed
as described under panel (A). Four different concentrations of rifampicin (0, 5, 10, 20 µM) were used.
(D) Summary of the kinetics constants obtained for inhibition of Dox efflux byH 33342, verapamil
and rifampicin.
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FIGURE 5. The DrrAB system forms a multidrug transporter. (A.1) DrrAB-mediated H 33342
efflux in IOVs. The E. coli inside-out membrane vesicles were prepared, as described under Methods.
250 µg IOVs were mixed with 0.5 µM H 33342, 0.1 mg/ml creatine kinase and 5 mM creatine phosphate
in 3ml PBS buffer, pH 7.4.
The fluorescence spectra were recorded on an Alphascan-2spectrofluorometer with excitation of 355 nm and emission of 457 nm. After 100 s, the detection was
paused, and 1mM Mg2+ and 1mM ATP, pH 7.5 were added into the reaction. The detection was
continued for additional 250 s. Vector, IOVs prepared from cells containing empty vector; DrrAB, IOVs
prepared from cells expressing DrrAB. (A.2) Kinetic analysis of DrrAB-mediated H 33342 efflux in
IOVs. The experimental conditions were the same as described under A.1 above. However, H 33342
efflux was analyzed at concentrations ranging between 0.1 µM to 2.5 µM. The initial (between 100 s-200
s) linear rate of H 33342 efflux was determined. The data obtained from three independent experiments
were fitted by the Michaelis-Menten equation using Sigma Plot – Kinetics software in Single Substrate
Kinetics Format. (B.1) DrrAB-mediated EtBr efflux in E. coli cells. E. coli cells containing empty
vector or DrrAB were loaded with 25 µM EtBr for 1 hr at 37 °C. Energy was provided in the form of 20
mM glucose, and EtBr efflux was measured, as described under Methods. (B.2) Kinetic analysis of
DrrAB-mediated EtBr Efflux in E. coli cells. The experimental conditions were the same as described
under B.1 above. However, EtBr efflux was analyzed at concentrations ranging between 1 µM to 100
µM. The steady-state linear rate of EtBr efflux was determined. The data obtained from three
independent experiments were fitted by the Michaelis-Menten equation using Sigma Plot – Kinetics
software in Single Substrate Kinetics Format. (C) Summary of the kinetic parameters obtained by
using Michaelis-Menten or Hill equation for DrrAB-mediated Dox, H33342, and EtBr efflux.

TABLE 1. Bacterial strain and plasmids
Name
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(31)
(31)
(31)
(31)
(31)
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This study
This study
This study
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Description
Bacterial Strains or Plasmid
supE44 supF58 hsdR514 galK2 galT22 metB1 trpR55 lacY1 Δ
LE392 ΔuncIC
uncIC
Cloning
vector,
pACYC184
derivative, Cmr
pSU2718
drrAB in pSU2718, Cmr
pDX101
drrA in pSU2718, Cmr
pDX102
drrB in pSU2718, Cmr
pDX103
drrAB in pSU2718 with mutation of Gly44 to Ala44 in the
pDX101(G44A)
Walker A domain of drrA
drrAB
in
pSU2718
with
mutation of Gly44 to Ser44 in the
pDX101(G44S)
Walker A domain of drrA
drrAB in pSU2718 with mutation of Lys47 to Arg47 in the
pDX101(K47R)
Walker A domain of drrA
drrAB in pSU2718 with mutation of Ser141 to Arg141 in the
pDX101(S141R)
Signature domain of drrA
drrAB
in
pSU2718
with
mutation of Glu165 to Gln165 in the
pDX101(E165Q)
Walker B domain of drrA
drrAB in pSU2718 with mutation of Gln197 to His197 in the
pDX101(Q197H)
switch motif of drrA
drrAB in pSU2718 with mutation of Tyr198 to Arg198 in the
pDX101(Y198R)
switch motif of drrA
drrAB
in
pSU2718
with
mutation of Gln197 Tyr198 to His197
pDX101(Q197H/Y198R)
198
Arg in the switch motif of drrA
drrAB in pSU2718 with mutation of Gln197 Tyr198 to
pDX101(Q197H/Y198H)
His197His198 in the switch motif of drrA
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